Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Rosak

Showing results (11-20 of 31) with videos related to

Pageof 4
Sort By:
Hormone and Metabolic Research. Supplement Series|January 1, 1988
Biosynthetic human proinsulin, a new therapeutic compound for diabetics? A comparative study of biosynthetic human proinsulin with biosynthetic human insulinC Rosak, B O Boehm, P H Althoff, et al.
Deutsche Medizinische Wochenschrift (1946)|April 22, 1988
[Effectiveness of combined treatment with glibenclamide and insulin in secondary sulfonylurea failure. A controlled multicenter double-blind clinical trial]W Bachmann, N Lotz, H Mehnert, et al.
International Journal of Clinical Practice|August 31, 2006
Rosiglitazone is effective and well-tolerated in a range of therapeutic regimens during daily practice in patients with type 2 diabetesC Rosak, E Standl, T Reblin, et al.
Klinische Wochenschrift|February 26, 1991
Aspartic acid at position 57 of the HLA-DQ beta chain is protective against future development of insulin-dependent (type 1) diabetes mellitusB O Boehm, B Manfras, C Rosak, et al.
Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Metabolisme|October 1, 1986
Evidence for increased endogenous dopaminergic inhibition of aldosterone secretion in prolactinomaE Jungmann, U Schwedes, P H Althoff, et al.
Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Metabolisme|February 1, 1986
Endogenous dopaminergic inhibition of aldosterone and prolactin secretion is apparently not increased in primary aldosteronismE Jungmann, P H Althoff, C Rosak, et al.
Deutsche Medizinische Wochenschrift (1946)|December 20, 1985
[Combined treatment of type-2 diabetics with insulin and glibenclamide after secondary drug failure. Double-blind, insulin-placebo-controlled crossover study]C Rosak, O Schwarz, P H Althoff, et al.
International Journal of Clinical Practice|September 24, 2005
Rosiglitazone plus metformin is effective and well tolerated in clinical practice: results from large observational studies in people with type 2 diabetesC Rosak, R Petzoldt, R Wolf, et al.
Klinische Wochenschrift|September 1, 1986
Technical mishaps as easily avoidable causes of treatment failure when using pumps for pulsatile administration of gonadotropin-releasing hormoneK Schmidt, C Rosak, B Boehm, et al.
Deutsche Medizinische Wochenschrift (1946)|January 16, 1987
[Molecular biology of the adrenogenital syndrome. New possibilities of heterozygote screening]B O Böhm, C Rosak, T L Böhm, et al.
Pageof 4

Showing results (11-20 of 31) with videos related to

Sort By:
Pageof 4
Hormone and Metabolic Research. Supplement Series|January 1, 1988
Biosynthetic human proinsulin, a new therapeutic compound for diabetics? A comparative study of biosynthetic human proinsulin with biosynthetic human insulinC Rosak, B O Boehm, P H Althoff, et al.
Deutsche Medizinische Wochenschrift (1946)|April 22, 1988
[Effectiveness of combined treatment with glibenclamide and insulin in secondary sulfonylurea failure. A controlled multicenter double-blind clinical trial]W Bachmann, N Lotz, H Mehnert, et al.
International Journal of Clinical Practice|August 31, 2006
Rosiglitazone is effective and well-tolerated in a range of therapeutic regimens during daily practice in patients with type 2 diabetesC Rosak, E Standl, T Reblin, et al.
Klinische Wochenschrift|February 26, 1991
Aspartic acid at position 57 of the HLA-DQ beta chain is protective against future development of insulin-dependent (type 1) diabetes mellitusB O Boehm, B Manfras, C Rosak, et al.
Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Metabolisme|October 1, 1986
Evidence for increased endogenous dopaminergic inhibition of aldosterone secretion in prolactinomaE Jungmann, U Schwedes, P H Althoff, et al.
Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Metabolisme|February 1, 1986
Endogenous dopaminergic inhibition of aldosterone and prolactin secretion is apparently not increased in primary aldosteronismE Jungmann, P H Althoff, C Rosak, et al.
Deutsche Medizinische Wochenschrift (1946)|December 20, 1985
[Combined treatment of type-2 diabetics with insulin and glibenclamide after secondary drug failure. Double-blind, insulin-placebo-controlled crossover study]C Rosak, O Schwarz, P H Althoff, et al.
International Journal of Clinical Practice|September 24, 2005
Rosiglitazone plus metformin is effective and well tolerated in clinical practice: results from large observational studies in people with type 2 diabetesC Rosak, R Petzoldt, R Wolf, et al.
Klinische Wochenschrift|September 1, 1986
Technical mishaps as easily avoidable causes of treatment failure when using pumps for pulsatile administration of gonadotropin-releasing hormoneK Schmidt, C Rosak, B Boehm, et al.
Deutsche Medizinische Wochenschrift (1946)|January 16, 1987
[Molecular biology of the adrenogenital syndrome. New possibilities of heterozygote screening]B O Böhm, C Rosak, T L Böhm, et al.
Pageof 4